the leading contract development and manufacturing organisations, takes its first step into biologics manufacturing with the formal transfer of a majority stake in the Astrazeneca Biotech Laboratory, ABL, to its new subsidiary, Recipharm Biologics.
The transaction completed
on 1 January 2009. This modern facility adds mammalian recombinant protein and monoclonal antibody development and production capabilities to the group’s existing biopharmaceutical services.
retain a significant minority stake in the new company and under the terms of the arrangement, Recipharm will lease the ABL from Astrazeneca for an initial period of 12 years, purchasing all associated equipment and employing the existing staff.
This latest purchase
follows the company’s recent acquisition of lyophilisation facilities from Inotech Labor. Combined, these enable Recipharm to offer a one-stop bio-manufacturing shop, taking customers’ projects from cell-line development based on their gene of interest, right through to their finished products for pre-clinical and early clinical studies.
BREAKING